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Clinical Applicability of Newly Developed Image-based Cell Counter for 
Counting CD34＋ Cells: Comparison with Flow Cytometric Analysis
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Background: Flow cytometric analysis is the standard method for enumerating CD34＋ 
stem cells in hematopoietic stem cell transplantation. However, it has some limitations 
such as expensive instrumentation, high reagent costs, and discrepancies between tech-
nicians and laboratories. We compared counts of total nucleated cells (TNCs) and 
CD34＋ cells counts obtained from a flow cytometer with a newly-developed image- 
based microscopic cell counter (ADAM II) to evaluate the possibility of clinical applica-
tion of the ADAM II.
Methods: We used 18 samples of circulating peripheral blood (PB) and waste tube frac-
tions of peripheral blood stem cells (PBSCs) harvested by apheresis after G-CSF mobi-
lization from adult volunteer donors. We assessed the reproducibility and linearity of 
the new procedure and compared the numbers of TNCs and viable CD34＋ cells deter-
mined with the ADAM II and two different flow cytometers (FACSCalibur, FACSCanto II).
Results: Numbers of viable CD34＋ cells determined with the ADAM II were accurate 
over the expected range; the intra-assay coefficient of variation was ≤19.8%. Linearity 
was also satisfactory (R2=0.99). TNC counts obtained with the ADAM II were highly cor-
related with those obtained with the FACSCalibur (R2＞0.9841, P＜0.0001) and 
FACSCanto II (R2＞0.9620, P＜0.0001), as were the numbers of viable CD34＋ cells ob-
tained with the ADAM II and the FACSCalibur and FACSCanto II (R2＞0.9911, P＜0.0001 
and R2＞0.9791, P＜0.0001), respectively.
Conclusion: The newly developed image-based microscopic cell counter (ADAM II) ap-
pears to be suitable for enumerating TNCs and viable CD34＋ cells.
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Fig. 1. (A) The ADAM II image-based fluorescence cell counter: The instrument is a 4-channel (Bright field, PE, FITC and PerCP) 
bench-top assay platform equipped with state-of-the-art optics and a slide holder that accepts the ADAM II assay slide. The ADAM
II is based on quantitative fluorometric assay technology capable of quantifying single or multiple fluorophore(s) by measuring 
LED-induced fluorescence from stained cells in a single-use disposable slide. (B) The autofocusing system: the focus of the bright
or fluorescence image is aligned manually in advance by turning a nob, then the z-axis movement distance (focus value) from the
aligned position to the original stage position is calculated by an encoder sensor. Two or more channels (bright, fluorescence) for
each image position are individually measured and set in the system. Using the established positions for each channel (bright, 
fluorescence), the image is focused automatically and integrated image results are obtained. 
Introduction
The number of viable CD34＋ cells in peripheral blood 
(PB) as well as in graft products is the most important pa-
rameter for monitoring and predicting clinical outcomes af-
ter hematopoietic stem cell transplantation (HSCT) [1-3].
At present, flow cytometry and image-based analysis are 
the two main techniques used to count fluorescently la-
beled cells. Although flow cytometric analysis is the stand-
ard method for enumerating CD34＋ stem cells it has some 
limitations, such as expensive instrumentation and reagent 
costs, and poor reproducibility between technicians and 
laboratories. Image-based cell counting is based on in-
tegrating computer software for digital image analysis with 
fluorescence microscopy. They are also cost-effective, easy 
to use, and basically maintenance-free. Another benefit is 
that the procedures performed by technicians are very sim-
ple and standardized, so that inter-site and inter-technician 
variability should be minimized [4].
We have examined the ability of the ADAM II (NanoEntek, 
Seoul, Korea), a newly-developed image-based cell coun-
ter, to enumerate total nucleated cells (TNCs) and viable 
CD34＋ cells. To investigate the clinical applicability of the 
new equipment, we compared cell counts determined with 
it and those obtained with two types of flow cytometer. 
Materials and Methods
1) Blood samples
We used unmanipulated 18 samples of circulating PB 
and peripheral blood stem cells (PBSCs) obtained from 
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Fig. 2. The ADAM II-CD34 Coun-
ting Assay: blood samples of 20 L
are introduced into the ADAM II - 
CD34 tube containing lyophilized 
mixtures of fluorescent anti-CD34 
antibody and a nucleic acid dye 
for cell viability. Samples are mixed
and incubated for 20 minutes in 
the dark at room temperature 
(20oC to 25oC), RBC lysis buffer of
240 L is added and after 10 
minutes aliquots of 25 L are 
loaded into the CD34 Assay Slide 
and read.
adult volunteer donors by apheresis after G-CSF mobiliza-
tion. The PBSC were obtained from the tube segments that 
are usually discarded after cutting the apheresis tubes and 
retaining the harvested PBSC products. Written informed 
consent was obtained from all the volunteers prior to col-
lecting samples and this study was approved by the 
Institutional Review Board of Hanyang University Hospital 
(IRB 2015-04-029).
2) Flow cytometric analysis
Two different flow cytometers, a FACSCalibur (BD Bio-
science, San Jose, CA) and a FACSCanto II (BD Bioscience, 
San Diego, CA), in two different institutes were used. The 
flow cytometric analysis was performed using a BD SCE Kit 
(BD Bioscience, Franklin Lakes, NJ) according to the ISHAGE 
protocol [5]. The kit is designed to enumerate the viable 
dual-positive CD45＋dim/CD34＋ human stem cell population.
3) Image-based cell counting analysis
The image-based cell counter (ADAM II) uses a micro-
scopic cell counting technique with disposable microchips. 
The system is composed of a fluorescence microscope and 
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SD (cells/L) CV (%)
1 27.25 5.38 19.8
2 52.56 8.42 16.0
3 390.98 25.32 6.5
4 1,373.23 98.24 7.2
SD, standard deviation; CV, coefficient of variation.
Fig. 3. The linearity between CD34＋ cell counts as determined
by the ADAM II and expected CD34＋ cell counts in serially
diluted samples. Each analysis used 5 aliquots from a dilutions
(20-322 cells/L of sample). In dilution of 20 cells/L, mean 
CD34＋ cell counts was 17.36±2.71, CV (%) was 15.65. In 
dilution of 50 cells/L CD34＋ cell count was 47.94±3.84, CV
(%) was 8.00. In dilution of 100 cells/L, CD34＋ cell count
was 91.34±6.28, CV (%) was 6.87. In dilution of 280 cells/L,
CD34＋ cell count was 268.834±21.12, CV (%) was 7.86. In
all of the dilution range (20-322 cells/L), linearity was satis-
factory (R2=0.99).
image analyzer (Fig. 1A) equipped with autofocusing func-
tion (Fig. 1B). The ADAM II is designed to be used with 
the ADAM II assay slide loaded with cells stained with fluo-
rochromes (labeled antibodies against surface markers, as 
well as nucleic acid stains). The procedure is diagrammed 
in Fig. 2. The ADAM II captures simultaneously a series 
of bright field and fluorescence images and uses sophisti-
cated digital image analysis algorithms to count total (TNC) 
and fluorescent (CD34＋ cells) cells and calculate their 
concentrations. ADAMII takes multiple pictures (140 frames= 
7.8 microliter) and pools together to generate rare cell 
count data such as CD34. In each frame, the system takes 
three pictures (bright field, FITC channel, and PE channel) 
by rapidly changing optic channel so that each cell can be 
analyzed based on its size, shape (via bright field), viability 
(FITC channel using Sytox blue), and cell surface marker 
(PE channel using CD34-PE).
4) Reproducibility and linearity of the image-based cell 
counter
We first examined the linearity and reproducibility of the 
ADAM II. Linearity of the viable CD34＋ cell counts was 
confirmed over a range of dilutions (4-322 cells/L of sam-
ple). Linearity was considered adequate when R2＞0.98. 
Reproducibility was defined as the coefficient of variation 
(CV) of the assay around a specific value, and was consid-
ered sufficient when CV was not in excess of 20%.
5) Statistical analysis 
SPSS for Windows 16.0 (SPSS, Chicago, Illinois) was 
used for statistical analysis. Wilcoxon-ranksum test was 
used to compare the flow cytometers and ADAM II. 
Spearman correlation coefficients were used to assess the 
correlation of TNC and CD34＋ cell counts between the 
flow cytometers and ADAM II. Statistical significance (P＜ 
0.05) was determined with the nonparametric Wilcoxon 
test. The values of TNC and CD34＋ cell counts are median 
values which are descripted at result part.
Results
1) Reproducibility and linearity of the ADAM II
Each analysis used 20 aliquots from one sample, with ex-
pected values of 27-1,370 CD34＋ cells/L. The number of 
viable CD34＋ cells determined by ADAM II was sufficiently 
accurate over the expected range, and the intra-assay CV 
was ≤19.8% (Table 1). The linearity of CD34＋ cell counts 
was confirmed over a range of dilutions (4-322 cells/L of 
sample) as shown in Fig. 3. Linearity was satisfactory 
(R2=0.99).
2) Correlation between flow cytometers and ADAM II
In the samples of circulating PB, TNC counts were median 
of 42,193.5/L (range, 16,032.5-68,354.5/L) and 38,846.0/L 
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Fig. 4. (A) TNC/CD34＋ cell counts in PB determined by the ADAM II in the 2 different institutes and the FACSCalibur and FACSCanto 
II. There was no significant differences among different equipments. Column expressed as mean of cell counts and the bar expressed
as standard deviation. (B) TNC/CD34＋ cell counts in apheresis samples determined by the ADAM II in the 2 different institutes
and the FACSCalibur and FACSCanto II. There was no significant differences among different equipments. Column expressed as mean
of cell counts and the bar expressed as standard deviation.
(25,568.5-52,123.5/L) by the 2 flow cytometers, and 
45,068.5 L (27,901.5-62,235.5/L) and 36,373.0/L (20,320.5- 
52,425.5/L) by the ADAM II. CD34＋ cell counts were 
36.09/L (0.07-72.11/L) and 36.14/L (15.04-57.24/L) by 
the 2 flow cytometers, and 38.03/L (9.38-85.44/L) and 
39.06/L (16.31-61.81/L) by the ADAM II. In the samples 
from apheresis, TNC counts were 242,963.5/L (115,458.5- 
370,468.5/L) and 186,825.0/L (69,132.0-304,518.0/L) by 
the 2 flow cytometers, and 208,797.5/L (101,678.4- 
315,916.6/L) and 188,329.0/L (56,923.0-319,735.0/L) by 
the ADAM II. CD34＋ cell counts were 1,046.88/L (292.73- 
1,798.03/L) and 1,101.19/L (484.13-1,718.25/L) by the 
2 flow cytometers, and 1,114.29/L (166.62-2,081.96/L) 
and 1,122.05/L (495.75-1,748.35/L) by the ADAM II. The 
comparison of TNC counts between ADAM II and FACS in 
PB statistically showed no difference (P=0.240). In Apheresis, 
TNC counts between ADAM II and FACS also showed no 
difference (P=0.290). The TNC and CD34＋ cell counts ana-
lyzed by the flow cytometers in the 2 different institutes and 
by the ADAM II did not differ significantly (Fig. 4). The 
TNC and CD34＋ cell counts obtained with the ADAM II 
were highly correlated with those obtained with the 
FACSCalibur and FACSCanto II (Fig. 5).
Discussion
Flow cytometric quantification of CD34＋ cells has been 
widely used to optimize the mobilization and harvest of 
hematopoietic progenitor/stem cells for HSCT [5-7]. However, 
there are some disadvantages to flow cytometric analysis. 
Wee-Jin Rah, et al
130 Vol. 23, No. 2, October 2016
Fig. 5. Correlation between the TNC and CD34＋ cell counts in the ADAM II and FACSCalibur/FACSCanto II. The TNC counts 
obtained with the ADAM II were highly correlated with those obtained with the FACSCalibur (R2＞0.9841, P＜0.0001), and with
FACSCanto II (R2＞0.962, P＜0.0001), and the CD34＋ cell counts obtained with the ADAM II were highly correlated with those
obtained with the FACSCalibur and FACSCanto II (R2＞0.9911, P＜0.0001 and R2＞0.9791, P＜0.0001, respectively).
Flow cytometers, especially laser-based cell analyzers are 
expensive to buy and maintain. Additionally, since they are 
very sophisticated instruments, and only highly trained op-
erators can run them effectively. Furthermore, flow cy-
tometry protocols vary between institutions so that CD34＋ 
cell counts are generally poorly reproducible between tech-
nicians and laboratories [4,8,9].
Since the late 1990s, a range of image-based automated 
cell counters has been launched that provide precise data 
on cell numbers and viability. Kummrow et al. [10] and 
Kim et al. [11] compared the enumeration of viable blood 
cells using a microscopic cell counter and flow cytometer. 
Although Kim found a good correlation between micro-
scopic cell counter and flow cytometer, there is certain limi-
tation such as difficulty in detecting unstained cells by mi-
croscope, which could lead to overestimation of the per-
centages of live as well as dead cells.
In order to overcome the limitations of flow cytometry 
and improve image-based cell counting, we have devel-
oped the ADAM II, and have used it to enumerate TNCs 
and CD34＋ cells in this study [12]. The ADAM II is an im-
age-based fluorescence cell counter supplied with an 
Image-based Cell Counter
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all-in-one personal computer containing the software for 
the graphical user interface. It is based on quantitative fluo-
rometric assay technology capable of quantifying single or 
multiple fluorophore(s) by measuring LED-induced fluo-
rescence from stained cells in a single-use disposable slide. 
From a CD34-fluorochrome-stained and lysed sample, the 
ADAM II simultaneously captures a series of bright field 
and fluorescent images, then uses digital image analysis al-
gorithms to determine the CD34＋ cell concentrations as 
well as CD34＋ cell viability. Each image frame covers 
0.05525 L (850×650×100 mm3) and the counts from each 
frame, total 140 frames (7.8 L) are summed to generate 
total counts. In our study, the minimal TNC count was 
16,032.5/L, and ADAM II counts total 7.8 L for analyzing, 
so this meets the ISHAGE protocol which require at least 
80,000 cells. The ADAM II also has an autofocusing system 
to accurately discriminate between the cells and cell debris 
by morphology and size. Two or more different channels 
(bright, fluorescence) in a given image are individually 
measured and set in the system. Using different position 
value settings for each channel (bright, fluorescence), im-
age focusing is achieved automatically and integrated image 
results are obtained. In addition, Venditti et al [14] demon-
strated that a single staining with anti-CD34 antibody ap-
pears feasible and reliable to enumerate CD34＋ progenitor 
cells. These are the reason why we did not use the anti- 
CD45 antibody in ADAM II analysis.
In this study, we have established that cell counts de-
termined by ADAM II are accurate, and linear with cell 
concentration. In addition, numbers of TNC and viable 
CD34＋ cell counts obtained by ADAM II were highly cor-
related with those obtained by flow cytometry, even when 
the TNC counts in the ADAM II were obtained from the 
number of bright cells in the digital images without using 
anti-CD45 antibody. This study establishes the potential of 
the ADAM II, for providing consistent and reproducible 
counts of TNCs and viable CD34＋ cells. Furthermore, 
since the data obtained with the ADAM II were highly cor-
related with those obtained with the current standard meth-
od for enumerating cells, we anticipate that the ADAM II 
could have clinical application, since the procedure is 
straightforward, the equipment inexpensive and there is lit-
tle inter-site/-technician variability. In addition, ADAM II 
would be easily extended to enumerate various cell compo-
nents such as CD3＋, CD4＋, CD8＋ cells. Further studies 
of inter-site variability are warranted to confirm the superi-
ority of the newly developed equipment compared to flow 
cytometers.
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